Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
作者： Jin Hyun Park , Tae Min Kim , Bhumsuk Keam , Yoon Kyung Jeon , Se-Hoon Lee
DOI: 10.1016/J.CLLC.2012.10.007
关键词:
摘要: Abstract Background Although activating epidermal growth factor receptor ( EGFR ) mutations are excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most patients become resistant to gefitinib. Despite our knowledge the molecular basis acquired resistance, clinical have not been well elucidated. This study was undertaken evaluate with NSCLC and treated Patients Methods A total 170 received as a first-line (n = 50) second-line or more 120) treatment at Seoul National University Hospital. Treatment outcomes were compared between groups based on clinicopathologic factors, such line, metastatic site, mutation subtype. Results Survival similar greater (overall response rate, 2 P .832; progression-free survival [PFS], .373; overall [OS], .290). When number sites least 3, significantly reduced observed (median PFS 8.5 vs. 14.0 months, .002). In addition, presence 3 organs metastases an independent predictor (hazard ratio [HR] 1.97 [95% CI, 1.37-2.85]; .010). who failed respond within 6 months had lymph node metastasis than those responded later. Conclusions Tumor burden, expressed sites, is predictive inferior
sci-hub.se 参考文章(31)
James H. Goldie, Andrew J. Coldman, The genetic origin of drug resistance in neoplasms: implications for systemic therapy Cancer Research. ,vol. 44, pp. 3643- 3653 ,(1984)
Sae-Won Han, Tae-You Kim, Kyung-Hun Lee, Pil Gyu Hwang, Yoon Kyung Jeon, Do-Youn Oh, Se-Hoon Lee, Dong-Wan Kim, Seock-Ah Im, Doo Hyun Chung, Dae Seog Heo, Yung-Jue Bang, None, Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung Cancer. ,vol. 54, pp. 201- 207 ,(2006) , 10.1016/J.LUNGCAN.2006.07.007
E. L. Kaplan, Paul Meier, Nonparametric Estimation from Incomplete Observations Springer Series in Statistics. ,vol. 53, pp. 319- 337 ,(1992) , 10.1007/978-1-4612-4380-9_25
Brian M. Alexander, Megan Othus, Hale B. Caglar, Aaron M. Allen, Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. International Journal of Radiation Oncology Biology Physics. ,vol. 79, pp. 1381- 1387 ,(2011) , 10.1016/J.IJROBP.2009.12.060
J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C.-M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley, P. A. Janne, MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Science. ,vol. 316, pp. 1039- 1043 ,(2007) , 10.1126/SCIENCE.1141478
Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, Pasi A. Jänne, Olivier Kocher, Matthew Meyerson, Bruce E. Johnson, Michael J. Eck, Daniel G. Tenen, Balázs Halmos, EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib The New England Journal of Medicine. ,vol. 352, pp. 786- 792 ,(2005) , 10.1056/NEJMOA044238
Raffaella Sordella, Daphne W Bell, Daniel A Haber, Jeffrey Settleman, Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways Science. ,vol. 305, pp. 1163- 1167 ,(2004) , 10.1126/SCIENCE.1101637
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Rudolf A. Joss, Kurt Bürki, Peter Dalquen, Ernst Schatzmann, Serge Leyvraz, Franco Cavalli, Christian Ludwig, Pierre Siegenthaler, Pierre Alberto, Rolf Stahel, Eduard E. Holdener, Hansjörg Senn, Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer association of antitumor activity with initial tumor burden and treatment center Cancer. ,vol. 65, pp. 2426- 2434 ,(1990) , 10.1002/1097-0142(19900601)65:11<2426::AID-CNCR2820651104>3.0.CO;2-3
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938